Sanofi
SNY
Positions held
Your positionsSNY isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Sanofi is well-positioned in the healthcare sector with a strong market cap of approximately $94.8 billion, indicating investor confidence.
- Revenue increased by 9% compared to the prior quarter, reaching $12.3 billion.
- Gross margin improved to 75.5%, up from 72.1% in the previous quarter.
- Sanofi's earnings growth has declined significantly, with a -91.2% year-over-year change.
- The company's score indicates a 'Strong Sell' signal with a score of -29.00, reflecting negative market trends.
- Net income for 2025-Q4 was -$801 million, highlighting recent financial struggles.
Fundamentals
| Market cap | $96.40B | Enterprise value | $113.98B | Trailing P/E | 21.17 | Forward P/E | 7.45 |
| PEG | 27.71 | Price / book | 1.20 | Beta | 0.28 | Dividend yield | 6.01% |
| Revenue growth | 14.6% | Earnings growth | -91.2% | Gross margin | 73.5% | Operating margin | 21.0% |
| Profit margin | 8.1% | ROE | 5.7% | ROA | 5.1% | Debt / equity | 0.34 |
| Current ratio | 0.99 | Free cash flow | $6.30B | Analyst recommendation | buy | Mean target | $53.61 |
| 52w high | $52.68 | 52w low | $39.18 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $12.3B | $11.2B | $12.2B | $13.2B | $10.7B | — |
| Op margin | 19.4% | 20.2% | 13.4% | 28.7% | 18.1% | — |
| Net income | $343M | $1.6B | -$801M | $2.8B | $3.9B | — |
| Gross margin | 75.5% | 72.1% | 69.2% | 74.1% | 72.1% | — |
| Gross profit | $9.3B | $8.1B | $8.4B | $9.8B | $7.7B | — |
| Operating income | $2.4B | $2.3B | $1.6B | $3.8B | $1.9B | — |
- Revenue +9% vs prior quarter ($12.3B vs $11.2B).
- Gross margin 75.5% (was 72.1% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $46.7B | $44.3B | $41.6B | $40.6B | — |
| Op margin | 20.5% | 20.1% | 20.9% | 26.9% | — |
| Net income | $7.8B | $5.6B | $5.4B | $8.4B | — |
| Gross margin | 72.1% | 70.2% | 69.7% | 70.7% | — |
| Gross profit | $33.7B | $31.1B | $29.0B | $28.7B | — |
| Operating income | $9.6B | $8.9B | $8.7B | $10.9B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Vallourec (ENXTPA:VK) Names A New Digital Chief, Is It Still 32% Below Fair Value?
2026-10-08 · Pharma’s $500B patent problem will come in waves — not as a cliff
2026-10-08 · Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality
2026-10-07 · European Equities Traded in US as ADRs Fall in Wednesday Trading
2026-10-06 · Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
2026-10-06 · Health Care Roundup: Market Talk
2026-10-06 · Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
2026-10-06 · Press Release : Availability of the aide-mémoire for Q3 2026 results
2026-10-03 · Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
2026-10-02 · An $8 Billion Reason Why Regeneron Stock Is in Focus
Price (daily)
Full chart · RSI · MACD · patterns